for neuroendocrine tumours
- Targeted molecular therapy with Lutetium-DOTATATE for metastatic neuroendocrine group of tumours
- Mainstay of therapy is improvement in quality of life along with disease control
- Negligible adverse effects
Did you know ?
Compared to the standard octreotide (used in management of NET), PRRT shows a 79% improvement in progression-free survival